Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Spero Therapeutics Inc

Healthcare US SPRO

2.28USD
0.17(8.06%)

Last update at 2026-06-18T20:28:00Z

Day Range

2.152.51
LowHigh

52 Week Range

0.991.89
LowHigh

Fundamentals

  • Previous Close 2.11
  • Market Cap77.81M
  • Volume7100587
  • P/E Ratio3.28
  • Dividend Yield-%
  • EBITDA27.38M
  • Revenue TTM110.98M
  • Revenue Per Share TTM2.10
  • Gross Profit TTM -42.10700M
  • Diluted EPS TTM0.44

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -46.41500M -89.75600M -78.28000M -60.92500M -41.66200M
Minority interest - - - - 0.35M
Net income -48.02800M -91.30100M -77.51900M -60.17500M -41.66200M
Selling general administrative 36.48M 41.70M 21.44M 15.59M 12.89M
Selling and marketing expenses - - - - -
Gross profit 48.58M 18.26M 9.33M 4.74M 3.97M
Reconciled depreciation 0.87M 0.65M 0.76M 0.75M 0.41M
Ebit -42.19700M -87.97100M -79.87400M -63.96600M -43.21500M
Ebitda -18.93700M -87.37400M -79.11300M -63.21600M -42.80600M
Depreciation and amortization 23.26M 0.60M 0.76M 0.75M 0.41M
Non operating income net other - - 0.83M 2.29M 1.14M
Operating income -42.19700M -87.97100M -79.11300M -63.21600M -42.80600M
Other operating expenses 79.15M 106.23M 88.44M 67.96M 42.81M
Interest expense 2.60M 1.94M 0.00000M 0.00000M 0.30M
Tax provision - - - - -
Interest income 1.11M 0.35M 0.40M 1.33M 1.14M
Net interest income -1.49900M -1.59400M 0.40M 1.33M 1.14M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.61M 1.54M -0.76100M -0.75000M 1.14M
Total revenue 48.58M 18.26M 9.33M 4.74M 3.97M
Total operating expenses 79.15M 106.23M 88.44M 67.96M 42.81M
Cost of revenue - - - 65.78M 33.88M
Total other income expense net -4.21800M -1.78500M 0.83M 2.29M 1.14M
Discontinued operations - - - - -
Net income from continuing ops -46.41500M -89.75600M -78.28000M -60.92500M -41.66200M
Net income applicable to common shares -46.41500M -89.75600M -78.28000M -60.92500M -41.66200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 182.39M 124.80M 171.07M 153.45M 106.10M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.18M 3.38M 8.83M 6.06M 4.82M
Total liab 75.50M 48.87M 82.78M 21.41M 31.53M
Total stockholder equity 106.89M 75.93M 88.29M 132.04M 74.57M
Deferred long term liab - - - - -
Other current liab 6.94M 8.97M 14.35M 12.24M 21.59M
Common stock 0.05M 0.05M 0.03M 0.03M 0.02M
Capital stock 0.05M 0.05M 0.04M 0.03M 0.02M
Retained earnings -391.07200M -413.87800M -367.46300M -277.70700M -199.42700M
Other liab - 22.26M 58.14M 0.18M 0.25M
Good will - - - - -
Other assets 0.00000M 5.74M 5.64M 5.52M 3.54M
Cash 76.33M 109.11M 112.58M 85.21M 29.73M
Cash and equivalents - - - - -
Total current liabilities 37.15M 21.65M 18.67M 14.34M 26.66M
Current deferred revenue 27.11M 10.37M 1.86M - -
Net debt -70.79000M -102.46000M -105.24900M -77.37100M -24.18500M
Short term debt 1.72M 1.69M 1.36M 0.95M 0.93M
Short long term debt - - - - -
Short long term debt total 5.54M 6.65M 7.33M 7.84M 5.54M
Other stockholder equity 497.91M 489.76M 455.72M 409.72M 273.97M
Property plant equipment - 5.49M 7.56M 1.67M 7.15M
Total current assets 131.21M 109.11M 157.87M 126.91M 82.05M
Long term investments - - - - -
Net tangible assets - 75.93M 88.29M 132.04M 74.57M
Short term investments - 0.00000M 33.82M 41.70M 52.31M
Net receivables 50.70M 1.08M 2.64M 6.18M 8.55M
Long term debt - - - 0.18M 0.25M
Inventory 0.00000M -4.46300M -0.36100M -12.23900M -13.36900M
Accounts payable 1.38M 0.62M 1.10M 1.16M 4.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -0.00200M -0.00700M 0.02M
Additional paid in capital - - - - -
Common stock total equity - - - 0.03M 0.02M
Preferred stock total equity - - - 0.00300M -
Retained earnings total equity - - - -277.70700M -199.42700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.43M 10.20M 5.64M 17.76M 16.91M
Deferred long term asset charges - - - - -
Non current assets total 51.18M 15.70M 13.20M 26.55M 24.06M
Capital lease obligations 5.54M 6.65M 7.33M 7.84M 5.54M
Long term debt total - - - 0.18M 0.25M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 33.81M 7.67M 10.63M 29.84M -80.72000M
Change to liabilities 21.41M 10.59M -12.17700M 14.12M 3.66M
Total cashflows from investing activities 33.81M 7.67M 10.47M 29.53M -83.15600M
Net borrowings -54.48500M -54.48500M -54.48500M -54.48500M -
Total cash from financing activities -29.55300M 84.05M 130.88M 16.14M 69.52M
Change to operating activities -0.86800M -1.56000M -12.66500M 13.30M -2.56000M
Net income -46.41500M -89.75600M -78.28000M -60.92500M -41.66200M
Change in cash -3.47700M 27.38M 55.48M -4.35000M -53.25800M
Begin period cash flow 112.58M 85.21M 29.73M 34.08M 87.34M
End period cash flow 109.11M 112.58M 85.21M 29.73M 34.08M
Total cash from operating activities -7.73100M -64.34700M -85.87200M -50.02000M -39.62500M
Issuance of capital stock 24.51M 35.37M 129.65M 15.79M 70.50M
Depreciation 0.87M 0.65M 0.76M 0.75M 0.41M
Other cashflows from investing activities - - - 29.84M -80.72000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 1.20M 3.05M 2.43M -7.38400M 0.64M
Sale purchase of stock 10.28M 27.54M 14.18M 16.14M 69.52M
Other cashflows from financing activities -64.34300M 21.14M 52.22M 0.35M -0.97700M
Change to netincome 15.73M 11.90M 4.56M 3.72M 3.37M
Capital expenditures 0.00000M 0.04M 0.16M 0.31M 2.44M
Change receivables - - 2.18M -7.08500M 1.41M
Cash flows other operating - - -2.87800M 0.15M -6.13500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 55.48M -4.35000M -53.25800M
Change in working capital 22.09M 12.90M -13.39200M 6.83M -1.07100M
Stock based compensation 9.12M 9.43M 4.89M 3.78M 2.75M
Other non cash items 6.61M 2.37M 0.51M 0.36M -0.05000M
Free cash flow -7.73100M -64.30800M -86.02900M -50.33400M -42.06100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SPRO
Spero Therapeutics Inc		 0.17 8.06% 2.28 3.28 - 0.85 0.83 0.18 0.69
NVO
Novo Nordisk A/S		 -0.33 0.76% 43.19 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.18 2.68% 42.83 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.36 1.60% 451.63 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.01 0.33% 609.94 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Spero Therapeutics Inc

675 Massachusetts Avenue, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Dr. Ankit Mahadevia M.D., MBA Co-Founder, Pres, CEO & Director 1981
Mr. Satyavrat Shukla C.F.A. CFO & Treasurer 1972
Ted Jenkins VP & Head of Investor Relations NA
Ms. Tamara Lynn Joseph L.L.M. Chief Legal Officer 1963
Mr. James P. Brady Chief Human Resource Officer NA
Mr. Timothy Keutzer Chief Devel. Officer 1968
Dr. Ian A. Critchley Head of Clinical Microbiology NA
Dr. Susannah Walpole Ph.D. Head of Clinical Operations NA
Dr. Angela Talley M.D. Sr. VP of Clinical Devel. NA
Dr. Kamal Hamed M.B.A., M.D., M.P.H. Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions